DYAI
DYADIC INTL (DYAI)
NASDAQ
$0.70+$0.006 (+0.91%)
Price as of Jun 03, 2026 7:47 PM EDT
  • $29.4M
    Market Cap
  • -31.37%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 33
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Seriesâ„¢ on Wednesday, May 27 at 12:00 PM ET

Dyadic International, Inc. (Nasdaq: DYAI), a biotechnology company specializing in precision-engineered proteins and enzymes, will deliver a live interactive presentation at the Skyline Signature Series on May 27, 2026 at 12:00 PM ET. The event will allow investors to ask questions in real time and requires pre-registration.

05/21/2026, 3:45 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$0.67
$0.78
$0.69
1-Year Range
$0.68
$1.30
$0.69
Latest Close$0.69
Change
-$0.09 (-12.51%)
Volume514,918
Market Cap$29.4M
Shares Outstanding36.4M
P/E (TTM)-5.10
Diluted EPS (TTM)-$0.16
Enterprise Value$28.2M

Information as of 06/02/2026

Company Profile

DYADIC INTERNATIONAL INC
DYADIC INTERNATIONAL INC
https://www.dyadic.com
$29.4M
Market Cap
-$5.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094
561 743 8333

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Key Executives

  • Mark A. Emalfarb
  • Joseph Hazelton
  • Ping Wang Rawson
  • Ana Gómez Rodriguez

Current Ownership Distribution

  • Institutions85.5M (71.30%)
  • Mutual Funds20.9M (17.40%)
  • Insiders13.5M (11.30%)
  • Other0 (0.00%)